Table 2.
First-, second- and third- line chemotherapeutic regimens used
| First-line | Second-line | Third-line | |||
|---|---|---|---|---|---|
| Paclitaxel/carboplatin | 35 | Weekly paclitaxel/carboplatin | 28 | Carboplatin | 14 |
| Docetaxel/carboplatin | 12 | Docetaxel/carboplatin | 12 | Weekly paclitaxel/carboplatin | 10 |
| Paclitaxel/cisplatin | 7 | Irinotecan | 5 | Irinotecan | 8 |
| Topotecan | 2 | Irinotecan/etoposide | 4 | ||
| Carboplatin | 2 | Docetaxel | 4 | ||
| Liposomal doxorubicin | 1 | Liposomal doxorubicin | 4 | ||
| Paclitaxel/carboplatin | 1 | Docetaxel/carboplatin | 3 | ||
| Irinotecan/carboplatin | 1 | Cisplatin | 2 | ||
| Irinotecan/etoposide | 1 | Paclitaxel/carboplatin | 1 | ||
| Docetaxel | 1 | Paclitaxel/cisplatin | 1 | ||
| Irinotecan/mitomycin | 1 | ||||
| Paclitaxel | 1 | ||||
| Etoposide | 1 | ||||